Fig. 2: In vitro bioactivities of (−)-premarineosin A (3) and derivatives (4–12) show selectivity against Plasmodium falciparum. | Communications Chemistry

Fig. 2: In vitro bioactivities of (−)-premarineosin A (3) and derivatives (4–12) show selectivity against Plasmodium falciparum.

From: Metabolic engineering and late-stage functionalization expand the chemical space of the antimalarial premarineosin A

Fig. 2: In vitro bioactivities of (−)-premarineosin A (3) and derivatives (4–12) show selectivity against Plasmodium falciparum.

Compounds were evaluated against 3D7 (chloroquine-sensitive) and Dd2 (chloroquine-resistant) P. falciparum strains for antimalarial activity (48 h treatment) and the HEK293 embryonic kidney and MOLT4 T-cell leukemia lines for mammalian cell cytotoxicity (72 h treatment). EC50: half-maximal effective concentration. NA: Not assessed. SD: Standard Deviation.

Back to article page